2016, Number 1
Next >>
Rev Cent Dermatol Pascua 2016; 25 (1)
Alopecia by medications
Torres-González S, Morales-Sánchez MA, Gómez-Molinar VM
Language: Spanish
References: 23
Page: 5-10
PDF size: 263.41 Kb.
ABSTRACT
Drug-induced hair loss is a consequence of a toxic effect of the drug on the hair matrix. In this article we did a review of its clinical manifestation, focusing on the time of onset, the pattern of hair loss and the reversibility of the disease. We also describe the two forms of hair loss, telogen and anagen effluvium, their clinical characteristics and the drugs involved. The authors propose to perform the diagnostic approach in patients attendig for a severe hair loss. Finally, we report the case of a patient with telogen effluvium caused by pravastatin.
REFERENCES
Kligman AM. The human hair cycle. J Invest Dermatol. 1959; 33: 307-316.
Whiting DA. Chronic telogen effluvium. Dermatol Clin. 1996; 14: 723-731.
Tosti A, Pazzaglia M. Drug reactions affecting hair: diagnosis. Dermatol Clin. 2007; 25: 223-231.
Pillans PI, Woods DJ. Drug-associated alopecia. Int J Dermatol. 1995; 34: 149-158.
Yun SJ, Kim SJ. Hair loss pattern due to chemotherapy-induced anagen effluvium: a cross-sectional observation. Dermatology. 2007; 215: 36-40.
Patel M, Harrison S, Sinclair R. Drugs and hair loss. Dermatol Clin. 2013; 3: 67-73.
Trüeb RM. Chemotherapy-induced alopecia. Semin Cutan Med Surg. 2009; 28: 11-14.
Pareja B. Alopecia por medicamentos. Folia Dermatol (Perú). 1998; 9: 48-52.
Harrison S, Sinclair R. Telogen effluvium. Clin Exp Dermatol. 2002; 27: 389-395.
Sinclair R. Diffuse hair loss. Int J Dermatol. 1999; 38 (Suppl 1): 8-18.
Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol. 2008; 58: 545-570.
Rebora A, Guarrera M, Baldari M, Vecchio F. Distinguishing androgenetic alopecia from chronic telogen effluvium when associated in the same patient. Arch Dermatol. 2005; 141: 1243-1245.
Shapiro J, Wiseman M, Lui H. Practical management of hair loss. Can Fam Physician. 2000; 46: 1469-1477.
National Guideline Clearinghouse. Recommendations to diagnose and treat adult hair loss disorders or alopecia in primary care settings. Disponible en: www.guideline.gov.
Gummer CL. Cosmetics and hair loss. Clin Exp Dermatol. 2002; 27: 418-421.
Rushton DH. Nutritional factors and hair loss. Clin Exp Dermatol. 2002; 27: 396-404.
Trost JB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron a deficiency and its potential relationship to hair loss. J Am Acad Dermatol. 2006; 54: 824-844.
Hoffman R. TrichoScan: a novel tool for the analysis of hair growth in vivo. J Investig Dermatol Symp Proc. 2003; 8: 109-115.
Chadha V, Shenoi SD. Hair loss in cancer chemotherapeutic patients. Indian J Dermatol Venereol Leprol. 2003; 69: 131-132.
Duvic M, Lemak NA, Valero V, Hymes SR, Farmer KL, Hortobagyi GN et al. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol. 1996; 35: 74-78.
Ross EK, Shapiro J. Management of hair loss. Dermatol Clin. 2005; 23: 227-243.
Ridderheim M, Bjurberg M, Gustavsson A. Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitized scalp-cooling system used in 74 patients. Support Care Cancer. 2003; 11: 371-377.
Machuca M, Madeira de Souza C et al. Mission and vision of a clinical pharmacist throughout a possible case of iatrogenic alopecia. Pharm Care Esp. 2016; 18: 43-46.